AIP
RNTX

Ameritas Investment Partners’s Rein Therapeutics RNTX Stock Holding History

Ameritas Investment Partners’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-22
Closed -$3K – 3067
2018
Q1 		$3K Hold
22
– – ﹤0.01% 2912
2017
Q4 		$5K Buy
+22
New +$5.27K ﹤0.01% 2879

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Ameritas Investment Partners's RNTX Position: Q2 2018 in Review

Ameritas Investment Partners sold out of Rein Therapeutics (RNTX) in Q2 2018, closing a stake of 22 shares — an estimated $3K sold.

Ameritas Investment Partners first reported a position in RNTX in Q4 2017 and held it in 2 quarters. The position peaked at $5K in Q4 2017. 20 funds tracked by Wall St. Rank hold RNTX as of Q2 2018.

  • Ameritas Investment Partners reported no remaining Rein Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Ameritas Investment Partners sold 22 Rein Therapeutics shares in Q2 2018, an estimated $3K.
  • Ameritas Investment Partners first reported a position in Rein Therapeutics in Q4 2017 and held it in 2 quarters.
  • Ameritas Investment Partners's Rein Therapeutics position peaked at $5K in Q4 2017.
  • 20 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2018.

Based on Ameritas Investment Partners's 13F filing for Q2 2018, filed 13 Aug 2018.